AA
ACET icon

ALPS Advisors’s Adicet Bio ACET Stock Holding History

ALPS Advisors’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,368
Closed -$311K – 1020
2022
Q3 		$311K Sell
1,368
-115
-8% -$29.2K ﹤0.01% 722
2022
Q2 		$347K Buy
+1,483
New +$326K ﹤0.01% 700
2018
Q4 		– Sell
-443
Closed -$751K – 870
2018
Q3 		$751K Buy
443
+80
+22% +$104K ﹤0.01% 451
2018
Q2 		$372K Buy
+363
New +$391K ﹤0.01% 810

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

ALPS Advisors's ACET Position: Q4 2022 in Review

ALPS Advisors sold out of Adicet Bio (ACET) in Q4 2022, closing a stake of 1,368 shares — an estimated $311K sold.

ALPS Advisors first reported a position in ACET in Q2 2018 and held it in 4 quarters. The position peaked at $751K in Q3 2018. 100 funds tracked by Wall St. Rank hold ACET as of Q4 2022.

  • ALPS Advisors reported no remaining Adicet Bio position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 1,368 Adicet Bio shares in Q4 2022, an estimated $311K.
  • ALPS Advisors first reported a position in Adicet Bio in Q2 2018 and held it in 4 quarters.
  • ALPS Advisors's Adicet Bio position peaked at $751K in Q3 2018.
  • 100 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.